{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T16:39:08Z","timestamp":1790872748781,"version":"4.1.0"},"reference-count":58,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T00:00:00Z","timestamp":1701388800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100005416","name":"Norges Forskningsr\u00e5d","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100005416","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008730","name":"Kreftforeningen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008730","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007793","name":"Stiftelsen Kristian Gerhard Jebsen","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008363","name":"Kr\u00e6ftens Bek\u00e6mpelse","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008363","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Discov."],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>The principle of drug sensitivity testing is to expose cancer cells to a library of different drugs and measure its effects on cell viability. Recent technological advances, continuous approval of targeted therapies, and improved cell culture protocols have enhanced the precision and clinical relevance of such screens. Indeed, drug sensitivity testing has proven diagnostically valuable for patients with advanced hematologic cancers. However, different cell types behave differently in culture and therefore require optimized drug screening protocols to ensure that their ex vivo drug sensitivity accurately reflects in vivo drug responses. For example, primary chronic lymphocytic leukemia (CLL) and multiple myeloma (MM) cells require unique microenvironmental stimuli to survive in culture, while this is less the case for acute myeloid leukemia (AML) cells. Here, we present our optimized and validated protocols for culturing and drug screening of primary cells from AML, CLL, and MM patients, and a generic protocol for cell line models. We also discuss drug library designs, reproducibility, and quality controls. We envision that these protocols may serve as community guidelines for the use and interpretation of assays to monitor drug sensitivity in hematologic cancers and thus contribute to standardization. The read-outs may provide insight into tumor biology, identify or confirm treatment resistance and sensitivity in real time, and ultimately guide clinical decision-making.<\/jats:p>","DOI":"10.1038\/s41420-023-01722-5","type":"journal-article","created":{"date-parts":[[2023,12,1]],"date-time":"2023-12-01T13:02:41Z","timestamp":1701435761000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":22,"title":["Standardized assays to monitor drug sensitivity in hematologic cancers"],"prefix":"10.1038","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-9799-3680","authenticated-orcid":false,"given":"Pilar","family":"Ayuda-Dur\u00e1n","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3830-2277","authenticated-orcid":false,"given":"Johanne U.","family":"Hermansen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariaserena","family":"Giliberto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yanping","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-2182","authenticated-orcid":false,"given":"Robert","family":"Hanes","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0270-8291","authenticated-orcid":false,"given":"Sandra","family":"Gordon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Heikki","family":"Kuusanm\u00e4ki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea M.","family":"Brodersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aram N.","family":"Andersen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2841-4697","authenticated-orcid":false,"given":"Kjetil","family":"Task\u00e9n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krister","family":"Wennerberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jorrit M.","family":"Enserink","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1630-356X","authenticated-orcid":false,"given":"Sigrid S.","family":"Sk\u00e5nland","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2023,12,1]]},"reference":[{"key":"1722_CR1","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1182\/blood.V41.1.7.7","volume":"41","author":"M Ogawa","year":"1973","unstructured":"Ogawa M, Bergsagel DE, McCulloch EA. Chemotherapy of mouse myeloma: quantitative cell cultures predictive of response in vivo. Blood. 1973;41:7\u201315.","journal-title":"Blood"},{"key":"1722_CR2","doi-asserted-by":"publisher","first-page":"1321","DOI":"10.1056\/NEJM197806152982401","volume":"298","author":"SE Salmon","year":"1978","unstructured":"Salmon SE, Hamburger AW, Soehnlen B, Durie BG, Alberts DS, Moon TE. Quantitation of differential sensitivity of human-tumor stem cells to anticancer drugs. N. Engl J Med. 1978;298:1321\u20137.","journal-title":"N. Engl J Med"},{"key":"1722_CR3","doi-asserted-by":"publisher","first-page":"154","DOI":"10.1056\/NEJM198301203080310","volume":"308","author":"DD Von Hoff","year":"1983","unstructured":"Von Hoff DD. Send this patient\u2019s tumor for culture and sensitivity. N. Engl J Med. 1983;308:154\u20135.","journal-title":"N. Engl J Med."},{"key":"1722_CR4","doi-asserted-by":"publisher","first-page":"372","DOI":"10.1158\/2159-8290.CD-21-0538","volume":"12","author":"C Kornauth","year":"2022","unstructured":"Kornauth C, Pemovska T, Vladimer GI, Bayer G, Bergmann M, Eder S, et al. Functional precision medicine provides clinical benefit in advanced aggressive hematologic cancers and identifies exceptional responders. Cancer Discov. 2022;12:372\u201387.","journal-title":"Cancer Discov"},{"key":"1722_CR5","doi-asserted-by":"publisher","first-page":"388","DOI":"10.1158\/2159-8290.CD-21-0410","volume":"12","author":"D Malani","year":"2022","unstructured":"Malani D, Kumar A, Br\u00fcck O, Kontro M, Yadav B, Helles\u00f8y M, et al. Implementing a functional precision medicine tumor board for acute myeloid leukemia. Cancer Discov. 2022;12:388\u2013401.","journal-title":"Cancer Discov"},{"key":"1722_CR6","doi-asserted-by":"publisher","first-page":"1994","DOI":"10.3324\/haematol.2021.280393","volume":"107","author":"SS Sk\u00e5nland","year":"2022","unstructured":"Sk\u00e5nland SS, Inngjerdingen M, Bendiksen H, York J, Spetalen S, Munthe LA, et al. Functional testing of relapsed chronic lymphocytic leukemia guides precision medicine and maps response and resistance mechanisms. An index case. Haematologica. 2022;107:1994\u20138.","journal-title":"Haematologica"},{"key":"1722_CR7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1186\/s13045-016-0258-1","volume":"9","author":"JT Leonard","year":"2016","unstructured":"Leonard JT, Raess PW, Dunlap J, Hayes-Lattin B, Tyner JW, Traer E. Functional and genetic screening of acute myeloid leukemia associated with mediastinal germ cell tumor identifies MEK inhibitor as an active clinical agent. J Hematol Oncol. 2016;9:31.","journal-title":"J Hematol Oncol"},{"key":"1722_CR8","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1038\/s41420-023-01426-w","volume":"9","author":"JU Hermansen","year":"2023","unstructured":"Hermansen JU, Yin Y, Urban A, Myklebust CV, Karlsen L, Melvold K, et al. A tumor microenvironment model of chronic lymphocytic leukemia enables drug sensitivity testing to guide precision medicine. Cell Death Discov. 2023;9:125.","journal-title":"Cell Death Discov"},{"key":"1722_CR9","doi-asserted-by":"publisher","first-page":"1416","DOI":"10.1158\/2159-8290.CD-13-0350","volume":"3","author":"T Pemovska","year":"2013","unstructured":"Pemovska T, Kontro M, Yadav B, Edgren H, Eldfors S, Szwajda A, et al. Individualized systems medicine strategy to tailor treatments for patients with chemorefractory acute myeloid leukemia. Cancer Discov. 2013;3:1416\u201329.","journal-title":"Cancer Discov"},{"key":"1722_CR10","doi-asserted-by":"publisher","first-page":"285","DOI":"10.1158\/0008-5472.CAN-12-1906","volume":"73","author":"JW Tyner","year":"2013","unstructured":"Tyner JW, Yang WF, Bankhead A 3rd, Fan G, Fletcher LB, Bryant J, et al. Kinase pathway dependence in primary human leukemias determined by rapid inhibitor screening. Cancer Res. 2013;73:285\u201396.","journal-title":"Cancer Res"},{"key":"1722_CR11","doi-asserted-by":"publisher","first-page":"4444","DOI":"10.1158\/1078-0432.CCR-22-1221","volume":"28","author":"Y Yin","year":"2022","unstructured":"Yin Y, Athanasiadis P, Karlsen L, Urban A, Xu H, Murali I, et al. Functional testing to characterize and stratify PI3K inhibitor responses in chronic lymphocytic leukemia. Clin Cancer Res. 2022;28:4444\u201355.","journal-title":"Clin Cancer Res"},{"key":"1722_CR12","doi-asserted-by":"publisher","first-page":"427","DOI":"10.1172\/JCI93801","volume":"128","author":"S Dietrich","year":"2018","unstructured":"Dietrich S, Oles M, Lu J, Sellner L, Anders S, Velten B, et al. Drug-perturbation-based stratification of blood cancer. J Clin Invest. 2018;128:427\u201345.","journal-title":"J Clin Invest"},{"key":"1722_CR13","doi-asserted-by":"publisher","first-page":"E7554","DOI":"10.1073\/pnas.1703094114","volume":"114","author":"SE Kurtz","year":"2017","unstructured":"Kurtz SE, Eide CA, Kaempf A, Khanna V, Savage SL, Rofelty A, et al. Molecularly targeted drug combinations demonstrate selective effectiveness for myeloid- and lymphoid-derived hematologic malignancies. Proc Natl Acad Sci USA. 2017;114:E7554\u201363.","journal-title":"Proc Natl Acad Sci USA"},{"key":"1722_CR14","doi-asserted-by":"publisher","first-page":"850","DOI":"10.1016\/j.ccell.2022.07.002","volume":"40","author":"D Bottomly","year":"2022","unstructured":"Bottomly D, Long N, Schultz AR, Kurtz SE, Tognon CE, Johnson K, et al. Integrative analysis of drug response and clinical outcome in acute myeloid leukemia. Cancer Cell. 2022;40:850\u201364.e9.","journal-title":"Cancer Cell"},{"key":"1722_CR15","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.ccell.2021.12.004","volume":"40","author":"A Letai","year":"2022","unstructured":"Letai A, Bhola P, Welm AL. Functional precision oncology: Testing tumors with drugs to identify vulnerabilities and novel combinations. Cancer Cell. 2022;40:26\u201335.","journal-title":"Cancer Cell"},{"key":"1722_CR16","doi-asserted-by":"publisher","first-page":"973","DOI":"10.1016\/j.tips.2022.08.009","volume":"43","author":"\u00c5 Flobak","year":"2022","unstructured":"Flobak \u00c5, Sk\u00e5nland SS, Hovig E, Task\u00e9n K, Russnes HG. Functional precision cancer medicine: drug sensitivity screening enabled by cell culture models. Trends Pharm Sci. 2022;43:973\u201385.","journal-title":"Trends Pharm Sci"},{"key":"1722_CR17","doi-asserted-by":"publisher","first-page":"e39","DOI":"10.1017\/erm.2022.32","volume":"24","author":"ST Williams","year":"2022","unstructured":"Williams ST, Wells G, Conroy S, Gagg H, Allen R, Rominiyi O, et al. Precision oncology using ex vivo technology: a step towards individualised cancer care? Expert Rev Mol Med. 2022;24:e39.","journal-title":"Expert Rev Mol Med"},{"key":"1722_CR18","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1177\/108705719900400206","volume":"4","author":"JH Zhang","year":"1999","unstructured":"Zhang JH, Chung TD, Oldenburg KR. A simple statistical parameter for use in evaluation and validation of high throughput screening assays. J Biomol Screen. 1999;4:67\u201373.","journal-title":"J Biomol Screen"},{"key":"1722_CR19","doi-asserted-by":"publisher","first-page":"1768","DOI":"10.3324\/haematol.2022.281692","volume":"108","author":"H Kuusanm\u00e4ki","year":"2023","unstructured":"Kuusanm\u00e4ki H, Kyt\u00f6l\u00e4 S, V\u00e4nttinen I, Ruokoranta T, Ranta A, Huuhtanen J, et al. Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia. Haematologica. 2023;108:1768\u201381.","journal-title":"Haematologica"},{"key":"1722_CR20","doi-asserted-by":"publisher","first-page":"2114","DOI":"10.1038\/leu.2017.69","volume":"31","author":"D Wang","year":"2017","unstructured":"Wang D, Fl\u00f8isand Y, Myklebust CV, B\u00fcrgler S, Parente-Ribes A, Hofgaard PO, et al. Autologous bone marrow Th cells can support multiple myeloma cell proliferation in vitro and in xenografted mice. Leukemia. 2017;31:2114\u201321.","journal-title":"Leukemia"},{"key":"1722_CR21","doi-asserted-by":"publisher","first-page":"589","DOI":"10.1111\/j.1365-2141.1991.tb08086.x","volume":"79","author":"P Sonneveld","year":"1991","unstructured":"Sonneveld P, Schoester M, de Leeuw K. In vitro Ig-synthesis and proliferative activity in multiple myeloma are stimulated by different growth factors. Br J Haematol. 1991;79:589\u201394.","journal-title":"Br J Haematol"},{"key":"1722_CR22","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1182\/bloodadvances.2019000122","volume":"4","author":"ZJ Walker","year":"2020","unstructured":"Walker ZJ, VanWyngarden MJ, Stevens BM, Abbott D, Hammes A, Langou\u00ebt-Astrie C, et al. Measurement of ex vivo resistance to proteasome inhibitors, IMiDs, and daratumumab during multiple myeloma progression. Blood Adv. 2020;4:1628\u201339.","journal-title":"Blood Adv"},{"key":"1722_CR23","doi-asserted-by":"publisher","first-page":"1241","DOI":"10.1002\/1878-0261.13191","volume":"16","author":"M Giliberto","year":"2022","unstructured":"Giliberto M, Thimiri Govinda Raj DB, Cremaschi A, Sk\u00e5nland SS, Gade A, Tj\u00f8nnfjord GE, et al. Ex vivo drug sensitivity screening in multiple myeloma identifies drug combinations that act synergistically. Mol Oncol. 2022;16:1241\u201358.","journal-title":"Mol Oncol"},{"key":"1722_CR24","doi-asserted-by":"publisher","first-page":"1153","DOI":"10.1002\/1878-0261.13153","volume":"16","author":"K Melvold","year":"2022","unstructured":"Melvold K, Giliberto M, Karlsen L, Ayuda-Dur\u00e1n P, Hanes R, Holien T, et al. Mcl-1 and Bcl-xL levels predict responsiveness to dual MEK\/Bcl-2 inhibition in B-cell malignancies. Mol Oncol. 2022;16:1153\u201370.","journal-title":"Mol Oncol"},{"key":"1722_CR25","doi-asserted-by":"publisher","first-page":"1040730","DOI":"10.3389\/fonc.2022.1040730","volume":"12","author":"M Giliberto","year":"2022","unstructured":"Giliberto M, Santana LM, Holien T, Misund K, Nakken S, Vodak D, et al. Mutational analysis and protein profiling predict drug sensitivity in multiple myeloma cell lines. Front Oncol. 2022;12:1040730.","journal-title":"Front Oncol"},{"key":"1722_CR26","doi-asserted-by":"publisher","first-page":"3366","DOI":"10.1182\/blood-2019-126609","volume":"134","author":"N Krall","year":"2019","unstructured":"Krall N, Meszaros N, Lind K, Vilagos B, Sill H, Vladimer GI. Functional precision medicine in AML: technical performance evaluation for in vitro diagnostics using high-throughput image-based screening of primary patient cells. Blood. 2019;134:3366.","journal-title":"Blood"},{"key":"1722_CR27","doi-asserted-by":"crossref","unstructured":"Struyf N, Arnroth C, Sunandar S, Bohlin A, Sofia B, Lehmann S, et al. Comparison of Data from Fresh and Frozen AML Samples for Functional Drug Testing. 2022;140:6290.","DOI":"10.1182\/blood-2022-157262"},{"key":"1722_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-018-36121-9","volume":"8","author":"JU Hermansen","year":"2018","unstructured":"Hermansen JU, Tj\u00f8nnfjord GE, Munthe LA, Task\u00e9n K, Sk\u00e5nland SS. Cryopreservation of primary B cells minimally influences their signaling responses. Sci Rep. 2018;8:17651.","journal-title":"Sci Rep."},{"key":"1722_CR29","first-page":"e58386","volume":"140","author":"SS Sk\u00e5nland","year":"2018","unstructured":"Sk\u00e5nland SS. Phospho flow cytometry with fluorescent cell barcoding for single cell signaling analysis and biomarker discovery. JVisExp. 2018;140:e58386.","journal-title":"JVisExp"},{"key":"1722_CR30","doi-asserted-by":"publisher","first-page":"327","DOI":"10.1007\/978-1-0716-2095-3_14","volume":"2449","author":"P Athanasiadis","year":"2022","unstructured":"Athanasiadis P, Ianevski A, Sk\u00e5nland SS, Aittokallio T. Computational pipeline for rational drug combination screening in patient-derived cells. Methods Mol Biol. 2022;2449:327\u201348.","journal-title":"Methods Mol Biol"},{"key":"1722_CR31","doi-asserted-by":"publisher","first-page":"128","DOI":"10.1002\/pst.426","volume":"10","author":"JL Sebaugh","year":"2011","unstructured":"Sebaugh JL. Guidelines for accurate EC50\/IC50 estimation. Pharm Stat. 2011;10:128\u201334.","journal-title":"Pharm Stat"},{"key":"1722_CR32","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1038\/s42256-019-0122-4","volume":"1","author":"A Ianevski","year":"2019","unstructured":"Ianevski A, Giri AK, Gautam P, Kononov A, Potdar S, Saarela J, et al. Prediction of drug combination effects with a minimal set of experiments. Nat Mach Intell. 2019;1:568\u201377.","journal-title":"Nat Mach Intell"},{"key":"1722_CR33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1080\/1042819021000055129","volume":"44","author":"JA Martinez-Climent","year":"2003","unstructured":"Martinez-Climent JA, Sanchez-Izquierdo D, Sarsotti E, Blesa D, Benet I, Climent J, et al. Genomic abnormalities acquired in the blastic transformation of splenic marginal zone B-cell lymphoma. Leuk Lymphoma. 2003;44:459\u201364.","journal-title":"Leuk Lymphoma"},{"key":"1722_CR34","first-page":"5193","volume":"4","author":"B Yadav","year":"2014","unstructured":"Yadav B, Pemovska T, Szwajda A, Kulesskiy E, Kontro M, Karjalainen R, et al. Quantitative scoring of differential drug sensitivity for individually optimized anticancer therapies. SciRep. 2014;4:5193.","journal-title":"SciRep"},{"key":"1722_CR35","doi-asserted-by":"publisher","first-page":"btac840","DOI":"10.1093\/bioinformatics\/btac840","volume":"39","author":"R Hanes","year":"2023","unstructured":"Hanes R, Ayuda-Dur\u00e1n P, R\u00f8nneberg L, Nakken S, Hovig E, Zucknick M, et al. screenwerk: a modular tool for the design and analysis of drug combination screens. Bioinformatics. 2023;39:btac840.","journal-title":"Bioinformatics"},{"key":"1722_CR36","doi-asserted-by":"publisher","first-page":"1146486","DOI":"10.3389\/fonc.2023.1146486","volume":"13","author":"J Mollstedt","year":"2023","unstructured":"Mollstedt J, Mansouri L, Rosenquist R. Precision diagnostics in chronic lymphocytic leukemia: past, present and future. Front Oncol. 2023;13:1146486.","journal-title":"Front Oncol"},{"key":"1722_CR37","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1007\/s11864-022-00991-z","volume":"23","author":"JW Moore","year":"2022","unstructured":"Moore JW, Torres N, Superdock M, Mendler JH, Loh KP. How genetics can drive initial therapy choices for older patients with acute myeloid leukemia. Curr Treat Options Oncol. 2022;23:1086\u2013103.","journal-title":"Curr Treat Options Oncol"},{"key":"1722_CR38","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1007\/s11899-022-00674-4","volume":"17","author":"S Upadhyay Banskota","year":"2022","unstructured":"Upadhyay Banskota S, Khanal N, Marar RI, Dhakal P, Bhatt VR. Precision medicine in myeloid malignancies: hype or hope? Curr Hematol Malig Rep. 2022;17:217\u201327.","journal-title":"Curr Hematol Malig Rep."},{"key":"1722_CR39","doi-asserted-by":"publisher","first-page":"12888","DOI":"10.3390\/ijms232112888","volume":"23","author":"D Louren\u00e7o","year":"2022","unstructured":"Louren\u00e7o D, Lopes R, Pestana C, Queir\u00f3s AC, Jo\u00e3o C, Carneiro EA. Patient-derived multiple myeloma 3D models for personalized medicine-are we there yet? Int J Mol Sci. 2022;23:12888.","journal-title":"Int J Mol Sci"},{"key":"1722_CR40","doi-asserted-by":"publisher","first-page":"607608","DOI":"10.3389\/fonc.2020.607608","volume":"10","author":"C Scielzo","year":"2020","unstructured":"Scielzo C, Ghia P. Modeling the leukemia microenviroment in vitro. Front Oncol. 2020;10:607608.","journal-title":"Front Oncol"},{"key":"1722_CR41","doi-asserted-by":"publisher","first-page":"101601","DOI":"10.1016\/j.xpro.2022.101601","volume":"3","author":"D Belloni","year":"2022","unstructured":"Belloni D, Ferrarini M, Ferrero E, Guzzeloni V, Barbaglio F, Ghia P, et al. Protocol for generation of 3D bone marrow surrogate microenvironments in a rotary cell culture system. STAR Protoc. 2022;3:101601.","journal-title":"STAR Protoc"},{"key":"1722_CR42","doi-asserted-by":"publisher","first-page":"4235","DOI":"10.3390\/ijms24044235","volume":"24","author":"JR James","year":"2023","unstructured":"James JR, Curd J, Ashworth JC, Abuhantash M, Grundy M, Seedhouse CH, et al. Hydrogel-based pre-clinical evaluation of repurposed FDA-approved drugs for AML. Int J Mol Sci. 2023;24:4235.","journal-title":"Int J Mol Sci"},{"key":"1722_CR43","doi-asserted-by":"publisher","first-page":"2110","DOI":"10.1007\/s13346-022-01189-4","volume":"13","author":"A Dozzo","year":"2023","unstructured":"Dozzo A, Galvin A, Shin J-W, Scalia S, O\u2019Driscoll CM, Ryan KB. Modelling acute myeloid leukemia (AML): What\u2019s new? A transition from the classical to the modern. Drug Deliv Transl Res. 2023;13:2110\u201341.","journal-title":"Drug Deliv Transl Res"},{"key":"1722_CR44","doi-asserted-by":"publisher","first-page":"e595","DOI":"10.1016\/S2352-3026(17)30208-9","volume":"4","author":"B Snijder","year":"2017","unstructured":"Snijder B, Vladimer GI, Krall N, Miura K, Schmolke AS, Kornauth C, et al. Image-based ex-vivo drug screening for patients with aggressive haematological malignancies: interim results from a single-arm, open-label, pilot study. Lancet Haematol. 2017;4:e595\u2013e606.","journal-title":"Lancet Haematol"},{"key":"1722_CR45","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1158\/2643-3230.BCD-21-0219","volume":"3","author":"T Heinemann","year":"2022","unstructured":"Heinemann T, Kornauth C, Severin Y, Vladimer GI, Pemovska T, Hadzijusufovic E, et al. Deep morphology learning enhances ex vivo drug profiling-based precision medicine. Blood Cancer Discov. 2022;3:502\u201315.","journal-title":"Blood Cancer Discov"},{"key":"1722_CR46","doi-asserted-by":"publisher","first-page":"232","DOI":"10.1038\/s41589-018-0205-2","volume":"15","author":"C Schmidl","year":"2019","unstructured":"Schmidl C, Vladimer GI, Rendeiro AF, Schnabl S, Krausgruber T, Taubert C, et al. Combined chemosensitivity and chromatin profiling prioritizes drug combinations in CLL. Nat Chem Biol. 2019;15:232\u201340.","journal-title":"Nat Chem Biol"},{"key":"1722_CR47","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1177\/1087057113510401","volume":"19","author":"OJ Dressler","year":"2014","unstructured":"Dressler OJ, Maceiczyk RM, Chang S-I, deMello AJ. Droplet-based microfluidics: enabling impact on drug discovery. J Biomol Screen. 2014;19:483\u201396.","journal-title":"J Biomol Screen"},{"key":"1722_CR48","unstructured":"Auld DSP, Coassin PABS, Coussens NPP, Hensley P, Klumpp-Thomas C, Michael S, et al. Microplate Selection and Recommended Practices in High-throughput Screening and Quantitative Biology. In: Markossian S, Grossman A, Brimacombe K, Arkin M, Auld D, Austin C et al. (eds). Assay Guidance Manual [Internet]. Bethesda (MD): Eli Lilly & Company and the National Center for Advancing Translational Sciences; 2004. Bethesda (MD), 2020."},{"key":"1722_CR49","doi-asserted-by":"publisher","first-page":"313","DOI":"10.3390\/cells1030313","volume":"1","author":"H Ramachandran","year":"2012","unstructured":"Ramachandran H, Laux J, Moldovan I, Caspell R, Lehmann PV, Subbramanian RA. Optimal thawing of cryopreserved peripheral blood mononuclear cells for use in high-throughput human immune monitoring studies. Cells. 2012;1:313\u201324.","journal-title":"Cells"},{"key":"1722_CR50","doi-asserted-by":"publisher","first-page":"e0187440","DOI":"10.1371\/journal.pone.0187440","volume":"12","author":"BL H\u00f8nge","year":"2017","unstructured":"H\u00f8nge BL, Petersen MS, Olesen R, M\u00f8ller BK, Erikstrup C. Optimizing recovery of frozen human peripheral blood mononuclear cells for flow cytometry. PLoS ONE. 2017;12:e0187440.","journal-title":"PLoS ONE"},{"key":"1722_CR51","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.jim.2006.04.004","volume":"313","author":"AJ Garc\u00eda-Pi\u00f1eres","year":"2006","unstructured":"Garc\u00eda-Pi\u00f1eres AJ, Hildesheim A, Williams M, Trivett M, Strobl S, Pinto LA. DNAse treatment following thawing of cryopreserved PBMC is a procedure suitable for lymphocyte functional studies. J Immunol Methods. 2006;313:209\u201313.","journal-title":"J Immunol Methods"},{"key":"1722_CR52","doi-asserted-by":"publisher","first-page":"e76215","DOI":"10.1371\/journal.pone.0076215","volume":"8","author":"S Kutscher","year":"2013","unstructured":"Kutscher S, Dembek CJ, Deckert S, Russo C, K\u00f6rber N, Bogner JR, et al. Overnight resting of PBMC changes functional signatures of antigen specific T- cell responses: impact for immune monitoring within clinical trials. PLoS ONE. 2013;8:e76215.","journal-title":"PLoS ONE"},{"key":"1722_CR53","doi-asserted-by":"publisher","first-page":"708","DOI":"10.3324\/haematol.2018.214882","volume":"105","author":"H Kuusanm\u00e4ki","year":"2020","unstructured":"Kuusanm\u00e4ki H, Lepp\u00e4 A-M, P\u00f6l\u00f6nen P, Kontro M, Dufva O, Deb D, et al. Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia. Haematologica. 2020;105:708\u201320.","journal-title":"Haematologica"},{"key":"1722_CR54","doi-asserted-by":"publisher","first-page":"3204","DOI":"10.1016\/j.celrep.2017.03.018","volume":"18","author":"A Carey","year":"2017","unstructured":"Carey A, Edwards DK 5th, Eide CA, Newell L, Traer E, Medeiros BC, et al. Identification of interleukin-1 by functional screening as a key mediator of cellular expansion and disease progression in acute myeloid leukemia. Cell Rep. 2017;18:3204\u201318.","journal-title":"Cell Rep."},{"key":"1722_CR55","doi-asserted-by":"publisher","first-page":"1464","DOI":"10.1016\/j.drudis.2016.04.019","volume":"21","author":"SPS Dhami","year":"2016","unstructured":"Dhami SPS, Kappala SS, Thompson A, Szegezdi E. Three-dimensional ex vivo co-culture models of the leukaemic bone marrow niche for functional drug testing. Drug Discov Today. 2016;21:1464\u201371.","journal-title":"Drug Discov Today"},{"key":"1722_CR56","doi-asserted-by":"publisher","first-page":"52","DOI":"10.1016\/j.exphem.2020.08.004","volume":"90","author":"H Lin","year":"2020","unstructured":"Lin H, Damen JE, Walasek MA, Szilvassy SJ, Turhan AG, Louis SA, et al. Feeder-free and serum-free in vitro assay for measuring the effect of drugs on acute and chronic myeloid leukemia stem\/progenitor cells. Exp Hematol. 2020;90:52\u201364.e11.","journal-title":"Exp Hematol"},{"key":"1722_CR57","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1182\/blood.V85.4.997.bloodjournal854997","volume":"85","author":"BA Roecklein","year":"1995","unstructured":"Roecklein BA, Torok-Storb B. Functionally distinct human marrow stromal cell lines immortalized by transduction with the human papilloma virus E6\/E7 genes. Blood. 1995;85:997\u20131005.","journal-title":"Blood"},{"key":"1722_CR58","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1182\/blood-2016-02-699363","volume":"130","author":"R Karjalainen","year":"2017","unstructured":"Karjalainen R, Pemovska T, Popa M, Liu M, Javarappa KK, Majumder MM, et al. JAK1\/2 and BCL2 inhibitors synergize to counteract bone marrow stromal cell-induced protection of AML. Blood. 2017;130:789\u2013802.","journal-title":"Blood"}],"container-title":["Cell Death Discovery"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01722-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01722-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,3,27]],"date-time":"2024-03-27T12:02:57Z","timestamp":1711540977000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41420-023-01722-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,1]]},"references-count":58,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2023,12]]}},"alternative-id":["1722"],"URL":"https:\/\/doi.org\/10.1038\/s41420-023-01722-5","relation":{},"ISSN":["2058-7716"],"issn-type":[{"value":"2058-7716","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,12,1]]},"assertion":[{"value":"13 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2023","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"13 November 2023","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 December 2023","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"SSS has received honoraria from AbbVie and AstraZeneca, and research support from BeiGene and TG Therapeutics. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"The study was approved by the Regional Committee for Medical and Health Research Ethics of South-East Norway. All donors signed a written informed consent prior to sample collection. The research on human blood was carried out in accordance with the Declaration of Helsinki.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"435"}}